News – Page 1158 – Endpoints News

SIGN UP

Porges: Gilead’s hep C bash is winding down and it doesn’t have a cure for the hangover

9 years ago

Shire punts late-stage biosimilars of Humira and Enbrel back to Momenta, Coherus

9 years ago

Cancer biotech upstart grabs $18M round, sets out to master relapsed prostate cancer

9 years ago

Bristol-Myers Squibb brings Opdivo to a joint immuno-oncology program with Nektar’s new T cell amplifier

9 years ago

Amgen hit with a setback as Kyprolis fails a key frontline trial for multiple myeloma

9 years ago

Kite’s groundbreaking CAR-T hits key study goal, heads to the FDA

9 years ago

Idera dumps its lead cancer drug program; Pfizer won’t split up after all

9 years ago

Array Bio surges on positive results for first stage of melanoma combo PhIII

9 years ago

FDA deals out pain, handing out its third punishing slap down for opioid Remoxy

9 years ago

3 for 3 in PhIII: GW Pharma racing to the FDA after bagging another late-stage epilepsy success

9 years ago

The Endpoints poll: Clinton v Trump and widespread fretting that the FDA just blundered badly

9 years ago

Regeneron, Sanofi win red-carpet treatment at the FDA for a blockbuster contender

9 years ago

AbbVie digs in for a long war as Amgen bags first OK for a Humira biosimilar

9 years ago

Novartis preps Zykadia for a frontline NSCLC pitch, but faces a tough rival in Roche; J&J, GSK hustle RA drug ...

9 years ago

Thumbs Up/Thumbs Down: The FDA damaged itself badly with the Sarepta OK

9 years ago

As politicians debate the priority review voucher program, the FDA is rooting for its demise

9 years ago

UniQure CEO Soland makes a quick exit as execs hammer out a new strategy

9 years ago

Alzheimer’s player AC Immune taps IPO for $58M raise, sees shares soar

9 years ago

Lundbeck, Otsuka take the latest hit on Alzheimer’s as PhIII drug flops

9 years ago

Zuckerberg-Chan win some respect for $3B biomedical project; AstraZeneca shutters another US office

9 years ago

The next Sage? Shkreli partner Ligand puts together another sweet startup package deal for Seelos

9 years ago

Teva gets a mixed bag of PhIII data as it lines up against a (better?) Neurocrine rival for tardive dyskinesia

9 years ago

The next checkpoints? Immuno-oncology upstart looks to find new ways to unleash T cells

9 years ago

Out of limbo, Sarepta is raising $225M and taking bids on a priority voucher as it revs up marketing

9 years ago

First page Previous page 1155 1156 115711581159 1160 1161 Next page Last page